secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2023-08-02T23:59:59+00:00
Accession:  0001193125-23-201735
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Teva elects Prof. Varda Shalev to Board effective Sep 1, 2023
-------------------------------------------------------------

- Prof. Varda Shalev elected as independent director, effective Sep 1, 2023, until 2024 annual meeting.
- Shalev is a healthcare executive, managing partner at Team8 Health VC, and professor at Tel Aviv University.
- No arrangements or material interests with other parties; compensation same as other non-executive directors.
- No family relationships with any director or executive officer of Teva.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000119312523201735/0001193125-23-201735-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000119312523201735/d512916d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-201735

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer